Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) (PROMETHEUS)
19. August 2019 aktualisiert von: Joshua M Hare
A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Intramyocardial Injection of Autologous Human Mesenchymal Stem Cells (MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction (MI) Undergoing Cardiac Surgery for Coronary Artery Bypass Grafting (CABG)
Heart attacks are a leading cause of death in both men and women in the United States.
When a person has a heart attack, blood is unable to reach a certain area of the heart, and if the blood supply is not re-established quickly, that area of the heart can suffer permanent damage.
While recovery from a heart attack can be managed through medications and lifestyle changes, these treatments can not reverse the original damage to the heart.
Current research is focusing on the development of cell-based therapies using stem cells to repair organs that have been irreversibly damaged by disease.
A specific form of stem cells, called adult mesenchymal stem cells (MSCs), has shown promise for heart repair.
This study will evaluate the safety and effectiveness of injecting MSCs into the heart to repair and restore heart function in people who have had a heart attack and who are having heart surgery for coronary artery bypass grafting (CABG).
Studienübersicht
Status
Beendet
Detaillierte Beschreibung
Participation in this study will last 18 months. Potential participants will undergo initial screening 5 to 7 weeks prior to CABG surgery. Screening will include a physical exam, blood draw, pregnancy test, questions about medical history, current medications, and alcohol or drug use, an electrocardiogram (ECG), magnetic resonance imaging (MRI) of the heart, questionnaires, an echocardiogram and a computed tomography (CT) scan. Eligible participants will then undergo two baseline visits within 6 weeks of their scheduled surgery. Baseline Visit 1 will consist of vital sign measurements, a bone marrow aspiration to obtain MSCs and a blood draw for a biomarker test. Baseline Visit 2 will include treadmill test, 6-minute walk test, pulmonary function (FEV1) study and a 48 Hour Ambulatory ECG. After the second baseline visit, participants will be assigned randomly to receive either MSCs or placebo after surgery.
On the day of surgery, once all of the bypass grafts have been placed, a high or low dose of MSCs or placebo will be injected into a damaged area of the heart that did not receive a bypass graft. After receiving the injections, participants will remain in the hospital for up to 7 days. During this stay, participants will undergo a daily blood draw, urine test, ECG, and ambulatory ECG monitoring for the first 96 hours after surgery.
Upon being discharged, participants will return for monthly visits for 6 months and for follow-up visits 12 and 18 months after surgery. These visits will repeat most initial screening and baseline tests. There will be one additional visit 14 days after surgery, which will include questions about side effects, a physical exam, and a 48-hour ambulatory ECG.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
9
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Florida
-
Miami, Florida, Vereinigte Staaten, 33136
- University of Miami Miller School of Medicine
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21205
- Johns Hopkins University School Of Medicine
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
21 Jahre bis 80 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Diagnosis of chronic ischemic heart failure caused by a heart attack
- Scheduled to undergo cardiac surgery for CABG
- Ejection fraction between 15% and 50%
- Presence of an akinetic or dyskinetic region by standard imaging
Exclusion Criteria:
- Glomerular filtration rate of less than 50 mL/min/1.73m2 at study entry
- Contraindication to performance of an MRI scan
- Bone marrow dysfunction, as evidenced by a 20% or more deviation from normal hematocrit, white blood cell count, or platelet values without another explanation
- A coagulopathy condition not due to a reversible cause (i.e., Coumadin)
- Known, serious radiographic contrast allergy
- Known allergies to penicillin or streptomycin
- Organ transplant recipient
- Clinical history of malignancy within 5 years of study entry (e.g., patients with prior malignancy must be disease free for 5 years), except curatively treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma
- Non-cardiac condition that limits lifespan to less than 1 year
- On chronic therapy with immunosuppressant medication
- Serum positive for HIV, hepatitis B, or hepatitis C
- Female who is pregnant, nursing, or of child-bearing potential and not practicing effective birth control methods
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Lower dose mesenchymal stem cell (MSC) injection
Participants will receive lower dose mesenchymal stem cell injections for a total of 2 x 10^7 cells
|
Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 10^7 cells.
The injections will be administered following completion of CABG surgery.
|
|
Experimental: Higher dose MSC injection
Participants will receive higher dose of mesenchymal stem cell injections for a total of 2 x 10^8 cells
|
Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 10^8 cells.
The injections will be administered following completion of CABG surgery.
|
|
Placebo-Komparator: (3) Placebo
Participants will receive placebo injections
|
Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Patients With Serious Adverse Events
Zeitfenster: 12 Months
|
Six-month post-CABG surgery serious adverse event (SAE) proportion of patients experiencing a composite of sustained ventricular arrhythmias, (lasting longer than 15 seconds), with hemodynamic compromise, sudden unexpected death at six months, ectopic tissue formation at 12 months by chest/abdomen/pelvis CT exam.
|
12 Months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Infarct Scar Size (ISS) Over 18 Month Period
Zeitfenster: Baseline, 6 Months, 18 Months
|
Change in infarct scar size (ISS) between baseline and 6-month and 18 month visits as determined by delayed contrast-enhanced MRI.
|
Baseline, 6 Months, 18 Months
|
|
Left Ventricular Function (LVF) in Region of MSC Injection
Zeitfenster: Assessed at Baseline and 18 Months
|
The Left Ventricular Function differences in the region of MSC injection were evaluated.
LVF is evaluated via ECHO as the percentage of ejected blood.
|
Assessed at Baseline and 18 Months
|
|
Regional Left Ventricular Wall Thickening
Zeitfenster: Assessed at Baseline and 18 months
|
Difference between baseline and 18 month regional left ventricular wall thickening as determined by MRI.
|
Assessed at Baseline and 18 months
|
|
Left Ventricular End Diastolic Wall Thickness
Zeitfenster: Assessed at Baseline and 18 months
|
Difference between the baseline and 18 month left ventricular end diastolic wall thickness as determined by MRI and echocardiogram.
|
Assessed at Baseline and 18 months
|
|
Change in Left Ventricular End Diastolic and Systolic Volume
Zeitfenster: Baseline, 6 Months, 18 Months
|
Change in left ventricular end diastolic and systolic volume as determined by MRI and echocardiogram.
|
Baseline, 6 Months, 18 Months
|
|
Change in Left Ventricular Ejection Fraction
Zeitfenster: Baseline to 6 Months, Baseline to 18 Months
|
Change between baseline to 6-month and 18-month left ventricular ejection fraction (LVEF) as determined by MRI and echocardiogram.
|
Baseline to 6 Months, Baseline to 18 Months
|
|
Change in Peak Volume Oxygen
Zeitfenster: Baseline, 6 Months, 18 Months
|
Change in Peak VO2 as determined by treadmill test (mL/mg/min) from Baseline to 6 and from baseline to 18 months
|
Baseline, 6 Months, 18 Months
|
|
Change in Six Minute Walk Test
Zeitfenster: Baseline, 6 Months, 18 Months
|
Change in Six Minute Walk Test (in meters) from Baseline to 6 Months and Baseline to 18 Months
|
Baseline, 6 Months, 18 Months
|
|
Change in NYHA Functional Class
Zeitfenster: Baseline to 6 Months, 6 months to 18 Months
|
Change in New York Heart Association (NYHA) Functional Classification based on patient's self reported activity level. Worsened: documented increase in limitations of physical activity as self-described by subject Improved: documented decrease in limitations of physical activity as self-described by subject Unchanged: no documented change in limitations of physical activity as self-described by subject |
Baseline to 6 Months, 6 months to 18 Months
|
|
Minnesota Living With Heart Failure Questionnaire Scores
Zeitfenster: Assessed at 6 Months and 18 Months
|
Minnesota Living with Heart Failure (MLHF) questionnaire has a total score from 0 to 105.
A higher score indicates that participants heart failure is preventing them from living their lives measured at two time points.
|
Assessed at 6 Months and 18 Months
|
|
Incidence of Major Adverse Cardiac Events (MACE)
Zeitfenster: 18 Months
|
Incidence of Major Adverse Cardiac Events (MACE).
A composite incidence of (1) death, (2) hospitalization for heart failure, or (3) non-fatal recurrent Ml.
|
18 Months
|
|
Number of Participants With Abnormal 48-Hour Ambulatory ECG Recordings
Zeitfenster: Assessed at 6 Months, 12 Months, and 18 Months
|
Ambulatory ECG monitoring is the most widely employed technology for the evaluation of a patient with symptoms suggestive of cardiac arrhythmia or conduction abnormality. When the patient returns for follow up the 48- Hour Ambulatory monitor provides the data to the site staff to detect any abnormal recordings based upon standard ECG protocol. |
Assessed at 6 Months, 12 Months, and 18 Months
|
|
Change in Pulmonary Function
Zeitfenster: Baseline, 6 Months, 12 Months, 18 Months
|
Change in Pulmonary Function from Baseline to 6 month, Baseline to 12 month, and Baseline to 18 month visits as measured by forced expiratory volume in 1 second (FEV1)
|
Baseline, 6 Months, 12 Months, 18 Months
|
|
Serial Troponin Values (ng/mL)
Zeitfenster: Assessed at Baseline, 12 hours, 24 hours, 36 hours, and 48 hours post CABG
|
Serial Troponin Values (ng/mL) Values from Baseline to 48 Hours Post CABG
|
Assessed at Baseline, 12 hours, 24 hours, 36 hours, and 48 hours post CABG
|
|
Creatinine Kinase - Muscle/Brain (MB) (ng/mL)
Zeitfenster: Assessed at Baseline, 12 Hours, 24 Hours, 36 Hours, and 48 hours post CABG
|
Creatinine Kinase MB (ng/mL) Values every 12 hours from Baseline to 48 Hours Post CABG
|
Assessed at Baseline, 12 Hours, 24 Hours, 36 Hours, and 48 hours post CABG
|
|
Number of Clinically Significant Laboratory Values
Zeitfenster: 18 Months
|
Clinically significant laboratory values are first determined via standard laboratory normal values from a CAP and CLIA certified Laboratory and then assessed by investigator based on specific patient conditions and disease state.
|
18 Months
|
|
Rate of Treatment Emergent Adverse Events
Zeitfenster: Assessed at 6 Months, 12 Months, and 18 Months
|
Rate of Treatment Emergent Adverse Events Post Coronary Artery Bypass Graft (CABG) at 6 Months, 12 Months, and 18 Months
|
Assessed at 6 Months, 12 Months, and 18 Months
|
|
Number of Abnormal Echocardiogram Readings 2 Days Post CABG.
Zeitfenster: Day 2
|
The number of abnormal Echocardiogram readings 2 Days Post CABG will be documented based on transthoracic Echocardiographic standards.
However, although Echocardiograms 2 days post CABG operation may show abnormalities which is standard in this population, this testing is instrumental because it measures End- diastolic wall thickness and Left ventricular volumes at end-diastole and end-systole.
|
Day 2
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Joshua M. Hare, MD, University of Miami
- Hauptermittler: Gary Gerstenblith, MD, Johns Hopkins University
- Hauptermittler: John V. Conte, MD, Johns Hopkins University
- Hauptermittler: Steven P. Schulman, MD, Johns Hopkins University
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. November 2007
Primärer Abschluss (Tatsächlich)
1. Juni 2011
Studienabschluss (Tatsächlich)
1. Juni 2011
Studienanmeldedaten
Zuerst eingereicht
2. Januar 2008
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
3. Januar 2008
Zuerst gepostet (Schätzen)
8. Januar 2008
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
10. September 2019
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
19. August 2019
Zuletzt verifiziert
1. August 2019
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 20070598
- U54HL081028 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Ja
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .